Navigation Links
Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
Date:7/7/2009

PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today the nomination of PSI-352938 ("PSI-938") as a lead development candidate from two series of purine analogs for the treatment of chronic hepatitis C virus (HCV) infection. PSI-938 is a proprietary nucleotide analog polymerase inhibitor of HCV that is being advanced into studies required for submission of an Investigational New Drug (IND) application with the FDA or equivalent foreign regulatory application.

"PSI-938 is particularly interesting to us since it differs from our pyrimidine analogs, R7128 and PSI-7851, because it has a complementary resistance profile and is metabolized through a different phosphorylation pathway," stated Michael Otto, PhD, Pharmasset's Chief Scientific Officer. "These differences may prove to be particularly important as we explore combinations of nucleos(t)ides in clinical development in the future."

Purine nucleos(t)ide analogs have many of the benefits of pyrimidine nucleos(t)ide analogs, like R7128 and PSI-7851, in that they have demonstrated in vitro activity across multiple genotypes, a higher barrier to resistance than other classes of HCV small molecules in development, and the potential to be combined with other direct acting antivirals targeting HCV. In addition, these purine analogs are also active against the S282T resistant variant selected in vitro by the pyrimidine analogs, and are metabolized to the active triphosphate form through a different phosphorylation pathway than the pyrimidines. Given these characteristics, purine and pyrimidine analogs have the potential to be combined as part of a future treatment regimen.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleos(t)ide analogs, a class of compounds which act to inhibit the enzymes required for viral replication. We currently have three clinical-stage product candidates. R7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys(R) plus Copegus(R) and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys(R) and Copegus(R) to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which recently began Phase 1 clinical studies and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended March 31, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
2. Pharmasset to Present at Deutsche Bank Healthcare Conference
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at Two Upcoming Investor Conferences
5. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
6. Pharmasset to Webcast an Investor Event from the AASLD Meeting
7. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
8. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
9. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
10. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
11. Pharmassets Underwriters Release Shares from Lock-Up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
(Date:2/6/2016)... ... February 06, 2016 , ... US Sports Camps is proud to sponsor ... event brings together top non-profit leaders, ultimate organizations, and coaches from around the US. ... Bay Area Disc Program Director of Youth and Education, describes this year YUCC as ...
(Date:2/6/2016)... Pekin, IL (PRWEB) , ... February 06, 2016 ... ... the recovery phases of eating disorder treatment helps to reduce the frequency and ... “Tasks of the Recovery Phase: Re-Establishing Healthy Identity and Purpose,” will explore the ...
(Date:2/5/2016)... ... February 05, 2016 , ... VeloReality ... lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability to an ... and manufacturing not only reduce the weight of the unit, they also enhance ...
(Date:2/5/2016)... ... 2016 , ... The event is being held on April 7, 2016 from ... Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and cure ... disease and is the architect of this informative event to raise awareness and funds ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 2016 Aethlon Medical, Inc. (Nasdaq: AEMD ), ... will be presenting at Source Capital Group,s 2016 Disruptive Growth ... at 2:15 p.m. ET on Wednesday, February 10, 2016.  ... taking place at 3:15 p.m. ET. http://www.aethlonmedical.com .  ... after the conclusion of the live event. The panel discussion ...
(Date:2/5/2016)... , February 5, 2016 ... market research report "Fetal (Labor & Delivery) and Neonatal ... Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, CPAP, Capnograph, ... MarketsandMarkets, This report studies the global market over the ... estimated at USD 6.28 Billion in 2015 and is ...
(Date:2/4/2016)... Feb. 4, 2016 For hospitals considering enrollment ... already participating in the program, the Health Resources and ... as the , Mega-Guidance , could have significant impact ... published in September 2016. Essential Insights , ... Marketing , summarizes the Mega-Guidance,s key proposed changes, including ...
Breaking Medicine Technology: